UGT2B17 and leukemia: This may well apply to a number of other cancer therapeutics given the recent report that GLI1-inducible glucuronidation imparts resistance to a broad spectrum of compounds including FDA-approved drugs such as methotrexate.19 Our observations warrant additional studies to appreciate the prevalence and the clinical implications of high UGT2B17 expression on outcomes of leukaemia patients.